You are implying ZNO is making a profit. IT ISN'T.
The $15 million/Q revenue (Note revenue NOT receipts) is currently a figure derived form 1 quarter's sales, and is NOT attributed to recurring quarterly revenues in those amounts in the Anns. It's an accounting thing. Revenue ca be booked that is scheduled to be received later in the year, in case you aren't aware. Free Cash Flow is KING.
With your expanded revenue comes expanded expense + US marketing. The fragmentation and agency mode of US private health system means marketing is very, very expensive. Your competition is behemoths like J&J, Beckett, DuPont...and thousands of mid level just in the developed world...(China and India are replicating every chemical ZNO uses open source chemical base, these are what its FDA approval hinges on).
The only short term (2 yr) road to profitability for ZNO is maintaining its current localised contract emphasis and reducing its high costs. They're choosing to throw the whole lot at growth, which is a LONG road in a market like this. 10 years ... with loads of MOAT risk. It may happen, but it may not, and it definitely won't happen ( Justifiable $Billion valuation) in a 5 yr time frame.
ZNO Price at posting:
$1.41 Sentiment: Sell Disclosure: Not Held
